Manon Huizing

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 348 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

Manon Huizing, Anther Keung, Hilde Rosing et al. · Journal of Clinical Oncology · 1993 · 313 citations · Full text

Medicine, Oncology, Pharmacology +16

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

Manon Huizing, Giuseppe Giaccone, Laurence J. van Warmerdam et al. · Journal of Clinical Oncology · 1997 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17

Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome

Tim Van den Wyngaert, Tom Claeys, Manon Huizing et al. · Annals of Oncology · 2008 · 138 citations · Full text

Medicine, Oncology, Surgery +5

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Peter Vuylsteke, Manon Huizing, Katarína Petráková et al. · Annals of Oncology · 2016 · 114 citations · Full text

Medicine, Oncology, Pharmacology +17